GlassScriptPhysician profile
Naurin Ehsan Ahmad
NPI 1215196316
$284,619.47
in general payments reported to CMS, 2019-2025
22 companies · $138K in 2025
The $138K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $99.99 · 2021: $59.40 · 2022: $247 · 2023: $34K · 2024: $111K · 2025: $138K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $209K · Travel and Lodging: $60K · Food and Beverage: $8,961 · Honoraria: $5,400 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $208,812.25 |
| Travel and Lodging | $60,327.60 |
| Food and Beverage | $8,960.85 |
| Honoraria | $5,400.00 |
| Education | $360.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $148,874.29 | 2022-2025 | Rinvoq, Skyrizi |
| Dermavant Sciences, INC. | $67,841.84 | 2023-2024 | Vtama |
| Genzyme Corporation | $30,540.69 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $27,133.03 | 2023-2025 | Dupixent, Libtayo |
| Organon LLC | $6,921.47 | 2025 | Vtama |
| Janssen Biotech, INC. | $832.79 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $461.72 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $341.69 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $212.40 | 2023-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $181.30 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $175.55 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $174.63 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $173.31 | 2019-2022 | |
| Almirall LLC | $149.51 | 2019 | |
| Janssen Scientific Affairs, LLC | $147.75 | 2023 | Tremfya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $131.75 | 2021-2023 | |
| Pfizer INC. | $107.08 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.35 | 2023-2025 | Cyltezo, Spevigo |
| Amgen INC. | $78.55 | 2024-2025 | Otezla, Otezla |
| Novo Nordisk INC | $20.00 | 2025 | Wegovy |
| Organogenesis INC. | $16.72 | 2023 | Puraply |
| Convatec INC. | $15.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naurin Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.